Literature DB >> 2062805

Pharmacokinetics and anticonvulsant activity of three monoesteric prodrugs of valproic acid.

K Badir1, A Haj-Yehia, T B Vree, E van der Kleijn, M Bialer.   

Abstract

The pharmacokinetics of valproic acid (VPA) were compared in dogs with those of the prodrugs ethyl valproate (E-VPA), trichloroethyl valproate (T-VPA), and valproyl valproate (V-VPA). Valproic acid, E-VPA, T-VPA, and V-VPA were administered intravenously and orally to six dogs at equimolar doses. The three VPA prodrugs were rapidly converted to VPA. The biotransformation was complete in the case of E-VPA and T-VPA but was only partial in the case of V-VPA. Because of the rapid conversion to the parent drug, after administration of the prodrugs, VPA plasma levels did not yield a sustained-release profile. Further, the anticonvulsant activity of prodrugs was compared in mice to that of VPA and valpromide (VPD). The anticonvulsant activity of E-VPA, T-VPA, and V-VPA was less than that of VPA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2062805     DOI: 10.1023/a:1015854118110

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  13 in total

Review 1.  Clinical pharmacokinetics of hypnotics.

Authors:  D D Breimer
Journal:  Clin Pharmacokinet       Date:  1977 Mar-Apr       Impact factor: 6.447

2.  Investigation in the dipropylacetic acid series, C8 and C9 branched chain ethylenic acids and amides.

Authors:  G Taillandier; J L Benoit-Guyod; C Laruelle; A Boucherle
Journal:  Arch Pharm (Weinheim)       Date:  1977-05       Impact factor: 3.751

3.  A comparative study on the pharmacokinetics of valpramide after intravenous administration in dogs.

Authors:  M Bialer; A Rubinstein
Journal:  J Pharm Pharmacol       Date:  1983-09       Impact factor: 3.765

4.  Antiepileptic Drug Development Program.

Authors:  R J Porter; J J Cereghino; G D Gladding; B J Hessie; H J Kupferberg; B Scoville; B G White
Journal:  Cleve Clin Q       Date:  1984

5.  Rapid gas chromatographic assay for monitoring valproic acid and valpromide in plasma.

Authors:  M Bialer; M Friedman; A Rubinstein
Journal:  J Pharm Sci       Date:  1984-07       Impact factor: 3.534

6.  Statistical moments in pharmacokinetics.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

7.  Dipropylacetic acid plasma levels; diurnal fluctuations during chronic treatment with dipropylacetamide.

Authors:  F Pisani; A Fazio; G Oteri; R Di Perri
Journal:  Ther Drug Monit       Date:  1981       Impact factor: 3.681

8.  Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers.

Authors:  M Bialer; A Rubinstein; I Raz; O Abramsky
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 9.  Clinical pharmacokinetics of valproic acid--1988.

Authors:  G Zaccara; A Messori; F Moroni
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

10.  Some clinical pharmacological aspects of n-dipropylacetamide.

Authors:  F Pisani; R Di Perri
Journal:  Ital J Neurol Sci       Date:  1980-10
View more
  3 in total

Review 1.  Valproic Acid: second generation.

Authors:  Meir Bialer; Boris Yagen
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

2.  Pharmacokinetics and antiepileptic activity of valproyl hydroxamic acid derivatives.

Authors:  M Levi; B Yagen; M Bialer
Journal:  Pharm Res       Date:  1997-02       Impact factor: 4.200

Review 3.  Can we develop improved derivatives of valproic acid?

Authors:  M Bialer; A Haj-Yehia; K Badir; S Hadad
Journal:  Pharm World Sci       Date:  1994-02-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.